Alaunos Therapeutics (NASDAQ:TCRT) Issues Earnings Results

Posted by Donald Scott on Apr 1st, 2026

Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) released its earnings results on Tuesday. The company reported ($0.36) earnings per share for the quarter, FiscalAI reports. The business had revenue of $0.00 million for the quarter.

Alaunos Therapeutics Trading Up 1.4%

TCRT opened at $2.86 on Wednesday. Alaunos Therapeutics has a 12 month low of $1.31 and a 12 month high of $6.20. The company has a market cap of $6.64 million, a PE ratio of -1.24 and a beta of -1.29. The company has a 50 day moving average of $2.96 and a 200 day moving average of $3.06.

Institutional Investors Weigh In On Alaunos Therapeutics

An institutional investor recently bought a new position in Alaunos Therapeutics stock. HRT Financial LP purchased a new stake in Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned approximately 0.54% of Alaunos Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 27.72% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alaunos Therapeutics in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Read Our Latest Stock Report on TCRT

Alaunos Therapeutics Company Profile

(Get Free Report)

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.